作为纤维化生物标志物的半乳糖凝集素-3如何改善心房颤动的诊断和预后？
How Can Galectin-3 as a Biomarker of Fibrosis Improve Atrial Fibrillation Diagnosis and Prognosis?
作者信息
da Silveira Maria Mariana Barros Melo, Cabral Joao Victor Batista, Souza Bruno de Melo, Hazime Louis Hussein Patu, Araujo Sara Larissa de Melo, Xavier Amanda Tavares, Mendes Filho Edivaldo Bezerra, Vasconcelos Luydson Richardson da Silva, Sobral Filho Dario Celestino, de Oliveira Dinaldo Cavalcanti
机构信息
Postgraduate Program in Therapeutic Innovation, Federal University of Pernambuco (PPGIT/UFPE), Recife, PE, Brazil.
Pernambuco Cardiovascular Emergency Room Teacher Luiz Tavares (PROCAPE/UPE), Recife, PE, Brazil.
出版信息
J Clin Med Res. 2020 Oct;12(10):647-654. doi: 10.14740/jocmr4313. Epub 2020 Sep 21.
Galectin-3 (Gal-3) is a biomarker of fibrosis that has been associated with atrial remodeling. Acknowledging the presence of a biomarker in patients with atrial fibrillation (AF) can allow for a better clinical treatment. The aim of this study was to assess the association of Gal-3 with atrial fibrosis in patients with AF. This is a systematic review study. From the total number of studies analyzed, 12 demonstrated a relation between atrial fibrosis and Gal-3 in patients with AF and presented statistically significant association values. We conclude that Gal-3 is associated with atrial fibrosis in patients with AF in all types, as well as after the arrhythmia treatment by ablation.
半乳糖凝集素-3（Gal-3）是一种纤维化生物标志物，与心房重构有关。认识到心房颤动（AF）患者中存在生物标志物有助于更好地进行临床治疗。本研究的目的是评估Gal-3与AF患者心房纤维化之间的关联。这是一项系统评价研究。在所分析的研究总数中，有12项表明AF患者的心房纤维化与Gal-3之间存在关联，并呈现出具有统计学意义的关联值。我们得出结论，Gal-3与所有类型AF患者的心房纤维化有关，也与心律失常消融治疗后的心房纤维化有关。
Zotero 插件